NCT04728360View on ClinicalTrials.gov

Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

556

Participants

Timeline

Start Date

July 6, 2021

Primary Completion Date

October 12, 2022

Study Completion Date

July 7, 2023

Conditions
Plaque Psoriasis
Interventions
DRUG

BAT2206

45 mg/0.5 mL

DRUG

Stelara (EU-sourced)

45 mg/0.5 mL

Trial Locations (1)

Unknown

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

Sponsors
All Listed Sponsors
lead

Bio-Thera Solutions

INDUSTRY